ATRC · investment memo
Four distinct questions, one field each. A price is not a thesis: the trigger below forces a re-underwrite and freezes further purchases — it is never an automatic sell.
A daily close below $35.83 triggers a mandatory re-underwrite and freezes further purchases. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.
Not stated. This name has no falsifiable invalidation conditions on file, so it cannot be risk-monitored. That is a gap in the research, not a clean bill of health — recorded rather than hidden.
Named cause: BoxX-NoAF misses its 30-day post-operative AF endpoint in H1 2027. This is the cleanest binary in the three-name set and it lands *inside* the 12-month horizon. ATRC's price requires an 18.91% revenue CAGR (see Valuation) against 12–14% guided — the gap is market *expansion*, and market expansion in cardiac surgery runs through the two trials. A BoxX-NoAF miss would: remove the prophylactic-ablation expansion thesis; strand the salesforce build management has flagged it would fund on a positive readout; and cast doubt on LeAAPS, whose readout is undated and which tests an adjacent